Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD47 | Q08722 | 1/20 | 0.69 |
| ▸ | IL23R | Q5VWK5 | 15/20 | 0.60 |
| ▸ | GLP1R | P43220 | 1/20 | 0.53 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | GIPR | P48546 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24172455 | 1.00 | CD47 (0.69) | CD47IL23RGLP1RGCGRGIPR | |
| SCHEMBL23913045 | 0.97 | CD47 (0.65) | CD47IL23R | |
| SCHEMBL21185976 | 0.91 | IL23R (0.63) | CD47IL23R | |
| SCHEMBL30092995 | 0.88 | IL23R (0.62) | CD47IL23R | |
| SCHEMBL30092992 | 0.88 | IL23R (0.62) | CD47IL23R | |
| SCHEMBL30092985 | 0.87 | IL23R (0.63) | CD47IL23R | |
| SCHEMBL30092909 | 0.87 | KISS1R (0.62) | CD47IL23R | |
| SCHEMBL16692892 | 0.86 | IL23R (0.61) | CD47IL23RGLP1RGCGRGIPR | |
| SCHEMBL16692898 | 0.86 | IL23R (0.61) | CD47IL23RGLP1RGCGRGIPR | |
| SCHEMBL24172454 | 0.86 | IL23R (0.61) | CD47IL23RGLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306124-B2 | Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | SORBONNE UNIVERSITE (FR) | 2022-04-19 | — | — | US | disclosed |
| EP-3454880-B1 | AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH | UNIV SORBONNE (FR) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306124-B2 | Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | CD47, BID, CD274 | CD47 1/4885IL23R 1029/4885GLP1R 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.